查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2088925

T細胞療法市場：依適應症、治療方法、生產模式、細胞來源和最終用戶分類－2026-2032年全球市場預測

T-Cell Therapy Market by Indication, Therapy Type, Manufacturing Model, Cell Source, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，T 細胞療法市場將成長至 343.4 億美元，複合年成長率為 21.57%。

主要市場統計數據
基準年 2025 87.5億美元
預計年份：2026年 105.9億美元
預測年份 2032 343.4億美元
複合年成長率 (%) 21.57%

T細胞療法市場正從實驗性腫瘤學轉向多元化的細胞療法生態系統，涵蓋CAR-T細胞療法、TCR療法、腫瘤浸潤淋巴細胞療法以及新興的異基因移植平台。自2017年CAR-T細胞療法首次獲得FDA批准以來，其適應症範圍已擴展至骨髓惡性腫瘤、多發性骨髓瘤、惡性黑色素瘤和滑膜肉瘤，這得益於在復發和難治性疾病中積累的臨床證據。

對於生物製藥創新者而言，策略重點不再侷限於概念驗證（PoC）。如今，競爭優勢取決於持續的臨床療效、可擴展的細胞療法生產、符合支付方偏好的真實世界數據、可靠的物流以及在先進醫學複雜框架內符合全球監管規定。

T細胞治療領域的變革性變化

該領域的發展趨勢正從單一產品上市轉向基於平台的開發。雖然自體CAR-T療法在臨床上仍然有效，但為了應對生產週期長、復發、抗原逃脫和獲取途徑受限等挑戰，人們正在設計異體T細胞療法、體內工程改造、基因編輯、強化T細胞構建體和雙靶點療法。

人工智慧對T細胞療法的累積影響

人工智慧正被擴大應用於各個領域，包括標靶發現、抗原檢驗、構建體設計、臨床試驗匹配、患者分層和生產品管。人工智慧驅動的分析有助於識別腫瘤抗原、預測T細胞適應性、檢測生產製程偏差、分析高階免疫譜數據，並支持複雜生物製藥的運輸測試。

全球T細胞療法的關鍵區域見解

北美仍然是T細胞療法商業化的領先中心，這得益於FDA在先進生技藥品的經驗、領先的學術癌症中心、專業的血液分離和輸注網路，以及已獲已通過核准的CAR-T細胞療法的成熟報銷途徑。在歐洲，EMA的集中核准、國家醫療技術評估流程、醫院豁免協議以及橫跨德國、法國、義大利、西班牙和英國的強大的細胞和基因治療研究叢集，都推動了T細胞療法的發展。

領先集團洞察，協助T細胞療法策略擴張

七國集團（G7）透過先進的監管體系、成熟的癌症治療保險報銷記錄、完善的臨床試驗基礎設施和先進的生物醫學研究能力，支持T細胞療法的尖端創新。歐盟透過歐洲藥品管理局（EMA）提供統一的上市許可，但將定價和准入決策權留給成員國，這導致CAR-T細胞療法、TCR療法和其他先進醫療產品的規模化應用和保險報銷流程都較為複雜。

各國對T細胞療法引入情況的深入了解

美國憑藉其獲得FDA已通過核准的CAR-T細胞療法種類繁多、早期應用範圍廣泛以及完善的認證治療中心網路，在CAR-T細胞療法的商業性應用方面處於領先地位。加拿大擁有強大的學術研究基礎和公共醫療體系，但各省之間的健保報銷制度存在差異。同時，墨西哥和巴西憑藉其不斷完善的基礎設施、轉診途徑以及在血液學和腫瘤學領域先進的醫療政策框架，為患者提供了長期的治療機會。

為行業領導者提供的實用建議

產業領導者應優先考慮確定適應症、開發差異化抗原策略、利用生物標記進行患者篩選，並產生證據以證明治療療效、安全性、生活品質改善以及整體醫療成本的永續性。由於T細胞療法初始成本高昂，且需要專門的白血球分離技術、淋巴球單採術、住院或門診監測以及毒性管理能力，因此與保險公司和醫療服務提供者儘早合作至關重要。

調查方法

本執行摘要是基於二手研究資料編寫而成，這些資料包括監管機構資訊、臨床試驗註冊資訊、同行評審文獻、腫瘤學指南、公共衛生技術評估資訊來源以及公開的行業資訊。本分析重點檢驗的市場訊號，包括產品核准、臨床開發趨勢、報銷趨勢、治療場所要求、安全監測措施以及生產限制。

結論

T細胞療法已成為精準腫瘤學領域最重要的方向之一，其中CAR-T細胞療法已奠定了商業性基礎，而TCR療法、TIL療法、異體移植平台和基因編輯技術則進一步拓展了治療前景。強大的轉化科學基礎、完善的監管先例、生產過程的改進以及復發、難治性及疑難癌症治療領域迫切的未滿足需求，都為該領域的發展提供了有力支撐。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 T細胞療法市場：依適應症分類

  • 自體免疫疾病
    • 多發性硬化症
    • 銀屑病
    • 類風濕性關節炎
  • 感染疾病
    • B型肝炎
    • C型肝炎
    • HIV
  • 腫瘤學
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
    • 固體癌
      • 乳癌
      • 肺癌
      • 黑色素瘤

第8章 T細胞療法市場：依療法類型分類

  • CAR-T細胞療法
  • TCR T細胞療法
  • TIL療法

第9章：T細胞療法市場：依生產模式分類

  • 契約製造
  • 內部生產

第10章 T細胞療法市場：依細胞來源分類

  • 同種異體移植
  • 本土種植

第11章 T細胞療法市場：以最終用戶分類

  • 醫院
  • 研究機構
  • 專科診所

第12章 T細胞療法市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 T細胞療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 T細胞療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Adaptimmune Therapeutics plc
  • Allogene Therapeutics Inc
  • ArsenalBio Inc
  • Atara Biotherapeutics Inc
  • Autolus Therapeutics plc
  • BioNTech SE
  • Brainchild Bio Inc
  • Bristol Myers Squibb Company
  • Cabaletta Bio Inc
  • Caribou Biosciences Inc
  • Cartesian Therapeutics Inc
  • Cellectis SA
  • Celyad Oncology SA
  • Eureka Therapeutics Inc
  • Fate Therapeutics Inc
  • Gilead Sciences Inc
  • Immatics NV
  • Iovance Biotherapeutics Inc
  • JW Therapeutics Co Ltd
  • Kite Pharma Incorporated
  • Kyverna Therapeutics Inc
  • Legend Biotech Corporation
  • Lyell Immunopharma Inc
  • Mustang Bio Inc
  • Novartis AG
  • Wugen Inc
Product Code: MRR-A26E0E5744D4

The T-Cell Therapy Market is projected to grow by USD 34.34 billion at a CAGR of 21.57% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.75 billion
Estimated Year [2026] USD 10.59 billion
Forecast Year [2032] USD 34.34 billion
CAGR (%) 21.57%

The T-cell therapy market is moving from experimental oncology toward a diversified adoptive cell therapy ecosystem spanning CAR T-cell therapy, TCR therapy, tumor-infiltrating lymphocyte therapy, and emerging allogeneic platforms. Since the first FDA approvals of CAR T therapies in 2017, regulatory acceptance has expanded across hematologic malignancies, multiple myeloma, melanoma, and synovial sarcoma, supported by growing clinical evidence in relapsed or refractory disease settings.

For biopharma innovators, the strategic priority is no longer proof of concept alone. Competitive advantage now depends on durable clinical outcomes, scalable cell therapy manufacturing, payer-aligned real-world evidence, reliable logistics, and global regulatory execution across complex advanced therapy frameworks.

Transformative Shifts in the T-Cell Therapy Landscape

The landscape is shifting from single-product launches to platform-based development. Autologous CAR T remains clinically validated, while allogeneic T-cell therapy, in vivo engineering, gene-editing, armored T-cell constructs, and dual-target approaches are designed to address manufacturing time, relapse, antigen escape, and access limitations.

Solid tumors are becoming the next frontier. The 2024 FDA approvals of lifileucel for unresectable or metastatic melanoma and afamitresgene autoleucel for synovial sarcoma reinforced that T-cell therapy is extending beyond blood cancers, although tumor microenvironment resistance, antigen heterogeneity, biomarker selection, and patient identification remain decisive hurdles.

Cumulative Impact of Artificial Intelligence in T-Cell Therapy

Artificial intelligence is increasingly embedded across target discovery, antigen validation, construct design, clinical trial matching, patient stratification, and manufacturing quality control. AI-enabled analytics can help identify tumor antigens, predict T-cell fitness, detect process deviations, analyze high-dimensional immune profiling data, and support release testing for complex living medicines.

The cumulative impact is operational as much as scientific. Sponsors that integrate AI with validated datasets, compliant automation, explainable models, and electronic batch records can shorten development cycles while improving consistency, but regulated deployment requires strong data governance, cybersecurity controls, auditability, and human oversight.

Key Regional Insights Across Global T-Cell Therapy

North America remains the leading commercialization hub for T-cell therapy, supported by FDA experience with advanced biologics, major academic cancer centers, specialized apheresis and infusion networks, and established reimbursement pathways for approved CAR T-cell therapies. Europe is advancing through EMA centralized approvals, national health technology assessment processes, hospital exemption experience, and strong cell and gene therapy research clusters across Germany, France, Italy, Spain, and the United Kingdom.

Asia-Pacific is accelerating through China, Japan, South Korea, India, Australia, and ASEAN markets, combining large patient populations with expanding clinical trial capacity, supportive regenerative medicine frameworks, and increasing domestic manufacturing capabilities. Latin America is earlier in adoption, with Brazil and Mexico strengthening oncology referral systems and advanced therapy policy discussions. The Middle East, particularly high-income Gulf health systems, is investing in precision medicine, specialty hospitals, and international oncology partnerships, while Africa remains at an earlier access stage but is gradually building cancer care infrastructure, diagnostic capacity, and referral networks that can support future T-cell therapy readiness.

Key Group Insights for Strategic T-Cell Therapy Expansion

The G7 anchors premium innovation in T-cell therapy through advanced regulatory systems, oncology reimbursement experience, mature clinical trial infrastructure, and deep biomedical research capacity. The European Union provides harmonized marketing authorization through the EMA while leaving pricing and access decisions to member states, creating both scale and reimbursement complexity for CAR T-cell therapy, TCR therapy, and other advanced therapy medicinal products.

BRICS markets are increasingly important for clinical development, patient recruitment, and localized manufacturing, especially China and India, where oncology burden, cost-conscious innovation, and domestic biomanufacturing policies are shaping future access models. ASEAN is building medical tourism, oncology capacity, and regional clinical research networks; the GCC is investing in advanced hospitals, precision medicine programs, and cross-border specialty care; and NATO-aligned countries benefit from research collaboration, biomedical supply chain resilience, and shared clinical standards that can support advanced cell therapy deployment.

Key Country Insights for T-Cell Therapy Adoption

The United States leads commercial adoption with multiple FDA-approved CAR T-cell therapies, expanding use in earlier treatment lines, and a dense network of certified treatment centers. Canada benefits from strong academic centers and public health system experience but faces provincial reimbursement variation, while Mexico and Brazil represent long-term access opportunities as hematology-oncology infrastructure, referral pathways, and advanced therapy policy frameworks continue to mature.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine regulatory maturity, specialist cancer centers, and active health technology assessment processes that influence patient access timelines and evidence expectations. Russia faces access, investment, and geopolitical constraints. China has become a major CAR T development and clinical research hub; India is advancing cost-conscious innovation and domestic cell therapy capabilities; Japan and South Korea support advanced regenerative medicine regulation and hospital-based innovation; and Australia remains a strong clinical trial destination with established oncology research networks and high-quality regulatory oversight.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize indication sequencing, differentiated antigen strategy, biomarker-enabled patient selection, and evidence generation that demonstrates durability, safety, quality of life improvement, and total cost-of-care value. Early payer and provider engagement is essential because T-cell therapies carry high upfront costs and require specialized leukapheresis, lymphodepletion, inpatient or outpatient monitoring, and toxicity management capabilities.

Manufacturers should invest in closed-system automation, decentralized or regionalized manufacturing models, cold-chain resilience, chain-of-identity controls, and digital vein-to-vein tracking. Partnerships with academic centers, contract development and manufacturing organizations, diagnostic developers, health systems, and AI specialists can reduce execution risk, accelerate site readiness, and improve consistency across clinical and commercial deployment.

Research Methodology

This executive summary is developed using secondary research from regulatory agencies, clinical trial registries, peer-reviewed literature, oncology guidelines, public health technology assessment sources, and publicly available industry disclosures. The analysis emphasizes verified market signals such as product approvals, clinical development trends, reimbursement dynamics, treatment center requirements, safety monitoring practices, and manufacturing constraints.

The methodology applies cross-validation across multiple credible sources to identify consistent patterns and reduce bias. Insights are structured around technology evolution, regional readiness, stakeholder economics, regulatory pathways, manufacturing feasibility, and commercialization requirements within the global T-cell therapy market, while avoiding unsupported market sizing or forecasting assumptions.

Conclusion

T-cell therapy has become one of the most important segments of precision oncology, with CAR T-cell therapy providing the commercial foundation and TCR therapy, TIL therapy, allogeneic platforms, and gene-edited approaches expanding the opportunity set. The field is supported by strong translational science, regulatory precedent, improving manufacturing methods, and urgent unmet need in relapsed, refractory, and difficult-to-treat cancers.

The next phase will reward organizations that combine clinical differentiation with manufacturing excellence, AI-enabled decision-making, robust real-world evidence, and equitable access strategies. Sustainable progress will depend on proving long-term value for patients, providers, payers, regulators, and health systems while improving reliability, affordability, and global availability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. T-Cell Therapy Market, by Indication

  • 7.1. Autoimmune Diseases
    • 7.1.1. Multiple Sclerosis
    • 7.1.2. Psoriasis
    • 7.1.3. Rheumatoid Arthritis
  • 7.2. Infectious Diseases
    • 7.2.1. Hepatitis B
    • 7.2.2. Hepatitis C
    • 7.2.3. HIV
  • 7.3. Oncology
    • 7.3.1. Leukemia
    • 7.3.2. Lymphoma
    • 7.3.3. Multiple Myeloma
    • 7.3.4. Solid Tumors
      • 7.3.4.1. Breast Cancer
      • 7.3.4.2. Lung Cancer
      • 7.3.4.3. Melanoma

8. T-Cell Therapy Market, by Therapy Type

  • 8.1. CAR T Cell Therapy
  • 8.2. TCR T Cell Therapy
  • 8.3. TIL Therapy

9. T-Cell Therapy Market, by Manufacturing Model

  • 9.1. Contract Manufacturing
  • 9.2. In-House Manufacturing

10. T-Cell Therapy Market, by Cell Source

  • 10.1. Allogeneic
  • 10.2. Autologous

11. T-Cell Therapy Market, by End User

  • 11.1. Hospital
  • 11.2. Research Institute
  • 11.3. Specialty Clinic

12. T-Cell Therapy Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. T-Cell Therapy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. T-Cell Therapy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Adaptimmune Therapeutics plc
  • 16.2. Allogene Therapeutics Inc
  • 16.3. ArsenalBio Inc
  • 16.4. Atara Biotherapeutics Inc
  • 16.5. Autolus Therapeutics plc
  • 16.6. BioNTech SE
  • 16.7. Brainchild Bio Inc
  • 16.8. Bristol Myers Squibb Company
  • 16.9. Cabaletta Bio Inc
  • 16.10. Caribou Biosciences Inc
  • 16.11. Cartesian Therapeutics Inc
  • 16.12. Cellectis SA
  • 16.13. Celyad Oncology SA
  • 16.14. Eureka Therapeutics Inc
  • 16.15. Fate Therapeutics Inc
  • 16.16. Gilead Sciences Inc
  • 16.17. Immatics NV
  • 16.18. Iovance Biotherapeutics Inc
  • 16.19. JW Therapeutics Co Ltd
  • 16.20. Kite Pharma Incorporated
  • 16.21. Kyverna Therapeutics Inc
  • 16.22. Legend Biotech Corporation
  • 16.23. Lyell Immunopharma Inc
  • 16.24. Mustang Bio Inc
  • 16.25. Novartis AG
  • 16.26. Wugen Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL T-CELL THERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL T-CELL THERAPY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL T-CELL THERAPY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL T-CELL THERAPY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL T-CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL T-CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEPATITIS B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEPATITIS B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEPATITIS B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEPATITIS C MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEPATITIS C MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HIV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HIV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HIV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CAR T CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CAR T CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CAR T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TCR T CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TCR T CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TCR T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TIL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TIL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TIL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN-HOUSE MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IN-HOUSE MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IN-HOUSE MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALLOGENEIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ALLOGENEIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALLOGENEIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AUTOLOGOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOLOGOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AUTOLOGOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RESEARCH INSTITUTE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RESEARCH INSTITUTE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RESEARCH INSTITUTE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL T-CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. GCC T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. GCC T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 160. GCC T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 161. GCC T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 163. GCC T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 165. GCC T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. G7 T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 190. G7 T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 191. G7 T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. G7 T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 195. G7 T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 196. G7 T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. NATO T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 200. NATO T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 201. NATO T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 203. NATO T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 205. NATO T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 323. INDIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 324. INDIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. INDIA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 326. INDIA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 327. INDIA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 331. JAPAN T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 332. JAPAN T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 333. JAPAN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 334. JAPAN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. JAPAN T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 336. JAPAN T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 337. JAPAN T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 338. AUSTRALIA T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 339. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 340. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 341. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 342. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 343. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 344. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 346. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 347. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 348. SOUTH KOREA T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 349. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 350. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 351. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 352. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 353. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 354. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 355. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 356. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 357. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)